文献速递眼底病与葡萄膜炎

阿柏西普治疗新生血管性年龄相关性黄斑变性中的黄斑萎缩与黄斑形态

MACULAR ATROPHY AND MACULAR MORPHOLOGY IN AFLIBERCEPT-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
PubMed 文献 · Retina · 2018-01-01

本研究纳入123只未治 subfoveal 新生血管性年龄相关性黄斑变性眼,接受3次每月负荷后每2月一次阿柏西普注射治疗12个月。13只眼(10.6%)在12个月时出现新发黄斑萎缩。基线存在视网膜内液和较薄的黄斑下脉络膜厚度与黄斑萎缩发生相关。

要点

  • 固定方案阿柏西普治疗12个月,约10.6%眼出现新发黄斑萎缩。
  • 基线视网膜内液存在与黄斑萎缩发生相关。
  • 基线黄斑下脉络膜厚度较薄与黄斑萎缩发生相关。

核心结论

  • 在固定方案阿柏西普治疗12个月期间,约10%的新生血管性年龄相关性黄斑变性眼发生黄斑萎缩。
  • 视网膜内液和黄斑下脉络膜厚度似乎是抗血管内皮生长因子(VEGF)治疗后黄斑萎缩发生的预测因素。

研究设计与样本

  • 本研究纳入2012年12月至2015年1月期间接受治疗的未治黄斑下新生血管性年龄相关性黄斑变性患者。
  • 患者第一年接受3次每月负荷注射后,每2月接受一次阿柏西普注射。
  • 视网膜色素上皮萎缩的诊断基于彩色眼底照相、频域光学相干断层扫描和眼底自发荧光。
  • 分析基线特征和形态学特征与黄斑萎缩发生的关联。

主要发现

  • 本研究纳入123只基线无黄斑萎缩并接受阿柏西普注射治疗12个月的眼。
  • 13只眼(10.6%)在12个月时出现新发黄斑萎缩。
  • 逻辑回归分析显示,基线存在视网膜内液和较薄的黄斑下脉络膜厚度与阿柏西普治疗后黄斑萎缩发生相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the incidence and predictors of macular atrophy during treatment with aflibercept for neovascular age-related macular degeneration in Japanese patients. METHODS: This study included patients with treatment-naive subfoveal neovascular age-related macular degeneration treated from December 2012 through January 2015. Patients were treated with bi-monthly aflibercept injections after 3 monthly loading injections for the first year. Diagnosis of retinal pigment epithelial atrophy was made based on color fundus photography, spectral-domain optical coherence tomography, and fundus autofluorescence. Baseline characteristics and morphological features were analyzed for their association with the development of macular atrophy. RESULTS: This study included 123 eyes that had no baseline macular atrophy and treated with aflibercept injections for 12 months. Thirteen eyes (10.6%) developed new macular atrophy at 12 months. Logistic regression analysis showed that the presence of intraretinal fluid and thinner subfoveal choroidal thickness at baseline were associated with the development of macular atrophy after aflibercept treatment. CONCLUSION: Macular atrophy developed in about 10% of eyes with neovascular age-related macular degeneration during 12 months of treatment with a fixed regimen of aflibercept. Intraretinal fluid and subfoveal choroidal thickness seem to be predictors for development of macular atrophy after anti-vascular endothelial growth factor (VEGF) therapy.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Kuroda Y, Yamashiro K, Ooto S, et al. MACULAR ATROPHY AND MACULAR MORPHOLOGY IN AFLIBERCEPT-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2018. PMID: 28691937. doi:10.1097/IAE.0000000000001765

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。